According to foreign media reports, on September 1, Nestlé announced that it plans to acquire a medical device company called Phagenesis, which is developing a medical device for the treatment of dysphagia. According to the terms of the agreement, Nestlé's Nestle Health Science will pay a certain amount of advance payment, after which, it will require Phagenesis to complete the evaluation of its product, Phasenix, in order to obtain follow-up funds. The acquisition plan will be phased in on the basis of the completion of clinical trials in Europe and the United States, which is expected to be completed in 2019. The specific amount of the acquisition is not disclosed by Nestlé, but according to the Wall Street Journal quoted people familiar with the matter, the purchase price of the medical device manufacturer of this size is about 100 million euros (about 130 million US dollars). Phagenyx, a new product developed by Phagenesis, is mainly used for patients with dysphagia. Currently, this symptom is common in diseases such as stroke and brain injury, which brings inconvenience to patients and families, and increases the financial burden of some families. According to statistics, this complication occurs in 29%-55% of patients, and this complication may cause many other diseases. It is reported that Phagenesis is headquartered in Manchester, England, and was established in 2007. Based on pharyngeal electronic stimulation, the company provides a solution to the problem of neurological dysphagia. CEO Reinhard Krickl said in an interview that the traditional treatment of dysphagia is focused on language therapy, which often takes weeks or months to work, and the Phagenesi method takes only a few days. Lactobacillus Gasseri,Lactobacillus Gasseri Probiotic,Lactobacillus Gasseri Products,Lactobacillus Gasseri Supplement Jiangsu Biodep Biotechnology Co. ,Ltd. , https://www.mbioda.com.jpg)
.jpg)